Literature DB >> 23836811

Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial.

Ioan Humphreys1, Avril E R Drummond, Ceri Phillips, Nadina B Lincoln.   

Abstract

OBJECTIVE: To evaluate the cost effectiveness of a psychological adjustment group shown to be clinically effective in comparison with usual care for people with multiple sclerosis.
DESIGN: Randomized controlled trial with comparison of costs and calculation of incremental cost effectiveness ratio.
SETTING: Community. PARTICIPANTS: People with multiple sclerosis were screened on the General Health Questionnaire 12 and Hospital Anxiety and Depression Scale, and those with low mood were recruited.
INTERVENTIONS: Participants randomly allocated to the adjustment group received six group treatment sessions. The control group received usual care, which did not include psychological interventions. MAIN MEASURES: Outcomes were assessed four and eight months after randomization, blind to group allocation. The costs were assessed from a service use questionnaire and information provided on medication. Quality of life was assessed using the EQ-5D.
RESULTS: Of the 311 patients identified, 221 (71%) met the criteria for having low mood. Of these, 72 were randomly allocated to receive treatment and 79 to usual care. Over eight months follow-up there was a decrease in the combined average costs of £378 per intervention respondent and an increase in the costs of £297 per patient in the control group, which was a significant difference (p=0.03). The incremental cost-effectiveness ratio indicated that the cost per point reduction on the Beck depression inventory-II was £118.
CONCLUSION: In the short term, the adjustment group programme was cost effective when compared with usual care, for people with multiple sclerosis presenting with low mood. The longer-term costs need to be assessed.

Entities:  

Keywords:  Beck depression inventory; Multiple sclerosis; cost effectiveness; mood; psychological therapy; quality of life

Mesh:

Year:  2013        PMID: 23836811     DOI: 10.1177/0269215513488608

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  6 in total

1.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

2.  A systematic review of economic analyses of psychological interventions and therapies in health-related settings.

Authors:  Leeanne Nicklas; Mairi Albiston; Martin Dunbar; Alan Gillies; Jennifer Hislop; Helen Moffat; Judy Thomson
Journal:  BMC Health Serv Res       Date:  2022-09-07       Impact factor: 2.908

Review 3.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 4.  Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis.

Authors:  Daniel Hind; Jack Cotter; Anna Thake; Mike Bradburn; Cindy Cooper; Claire Isaac; Allan House
Journal:  BMC Psychiatry       Date:  2014-01-09       Impact factor: 3.630

5.  Group-Based Individualized Comprehensive Core Stability Intervention Improves Balance in Persons With Multiple Sclerosis: A Randomized Controlled Trial.

Authors:  Ellen Christin Arntzen; Bjørn Kåre Straume; Francis Odeh; Peter Feys; Paolo Zanaboni; Britt Normann
Journal:  Phys Ther       Date:  2019-08-01

6.  Cost-effectiveness of nurse-delivered cognitive behavioural therapy (CBT) compared to supportive listening (SL) for adjustment to multiple sclerosis.

Authors:  I Mosweu; R Moss-Morris; L Dennison; T Chalder; P McCrone
Journal:  Health Econ Rev       Date:  2017-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.